Phaseline

Companies › Shanton Pharma Pte.

Shanton Pharma Pte.: clinical trials, targets and expected readouts

1 active drug program in 47 registered trials: 22 Phase 3, 13 Phase 2, 10 Phase 4, 2 Phase 1; Neurology, Cardiovascular, Genitourinary, Immunology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Colchicine (SAP-001)
Tubulin inhibitor
TubulinPhase 2Gout; Colchicine; Persistent Atrial Fibrillation; Coronary Artery Disease …–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05690204Colchicine (SAP-001)Phase 2GoutMetabolic and endocrineJan 2025
NCT06729853Colchicine (SAP-001)Phase 1GoutMetabolic and endocrineJan 2025
NCT06837623Colchicine (SAP-001)Phase 3HFpEF - Heart Failure With Preserved Ejection FractionCardiovascularFeb 2025
NCT04916522Colchicine (SAP-001)Phase 2HypertensionCardiovascularJan 2026
NCT05472337Colchicine (SAP-001)Phase 2Acute Coronary SyndromeCardiovascularMar 2026
NCT05162742Colchicine (SAP-001)Phase 3Aortic Valve DiseaseCardiovascularDec 2026
NCT07247734Colchicine (SAP-001)Phase 2Type 1 DiabetesImmunologyDec 2026
NCT07287345Colchicine (SAP-001)Phase 4ColchicineCardiovascularDec 2026
NCT06118034Colchicine (SAP-001)Phase 3Inflammatory ResponseCardiovascularDec 2026
NCT05890664Colchicine (SAP-001)Phase 3Atrial FibrillationCardiovascularMar 2027
NCT06765356Colchicine (SAP-001)Phase 4Persistent Atrial FibrillationCardiovascularMar 2027
NCT05850091Colchicine (SAP-001)Phase 4Coronary Artery DiseaseCardiovascularJun 2027
NCT05335148Colchicine (SAP-001)Phase 1Radiation TherapyImmunologyJun 2027
NCT05873881Colchicine (SAP-001)Phase 3Heart FailureCardiovascularJun 2027
NCT06472908Colchicine (SAP-001)Phase 3Coronary Heart DiseaseCardiovascularJun 2027
NCT06472908Colchicine (SAP-001)Phase 3Coronary Heart DiseaseCardiovascularJun 2027
NCT07571681Colchicine (SAP-001)Phase 2Hashimoto ThyroiditisImmunologyJul 2027
NCT07837934Colchicine (SAP-001)Phase 2Type 2 Diabetes Mellitus (T2DM)CardiovascularJul 2027
NCT05476991Colchicine (SAP-001)Phase 3StrokeCardiovascularSep 2027
NCT05503225Colchicine (SAP-001)Phase 2ICAD - Intracranial Atherosclerotic DiseaseCardiovascularSep 2027
NCT06802926Colchicine (SAP-001)Phase 4CABGOtherOct 2027
NCT06090890Colchicine (SAP-001)Phase 4In-stent RestenosisOtherOct 2027
NCT06095765Colchicine (SAP-001)Phase 3Coronary Artery DiseaseCardiovascularNov 2027
NCT07362966Colchicine (SAP-001)Phase 4ColchicineCardiovascularDec 2027
NCT06440694Colchicine (SAP-001)Phase 3Venous ThromboembolismCardiovascularDec 2027
NCT05633810Colchicine (SAP-001)Phase 3Diabete Type 2CardiovascularDec 2027
NCT07026994Colchicine (SAP-001)Phase 2Cerebral Amyloid AngiopathyNeurologyDec 2027
NCT06130059Colchicine (SAP-001)Phase 2Heart FailureCardiovascularDec 2027
NCT06763055Colchicine (SAP-001)Phase 3Intracerebral HemorrhageNeurologyJan 2028
NCT05855746Colchicine (SAP-001)Phase 3Acute MyocarditisImmunologyJan 2028
NCT06813079Colchicine (SAP-001)Phase 2Pancreatic Ductal CarcinomaOncologyFeb 2028
NCT06279000Colchicine (SAP-001)Phase 3Cardiovascular DiseasesCardiovascularMar 2028
NCT06158698Colchicine (SAP-001)Phase 3CardiomyopathiesCardiovascularMay 2028
NCT06286423Colchicine (SAP-001)Phase 4Heart FailureCardiovascularJun 2028
NCT05618353Colchicine (SAP-001)Phase 4Coronary Artery DiseaseCardiovascularJul 2028
NCT05928728Colchicine (SAP-001)Phase 3Atrial FibrillationCardiovascularNov 2028
NCT06543082Colchicine (SAP-001)Phase 4Acute Coronary SyndromeCardiovascularDec 2028
NCT07704164Colchicine (SAP-001)Phase 2HIV InfectionInfectious diseaseDec 2028
NCT06998862Colchicine (SAP-001)Phase 3Chronic Kidney DiseaseGenitourinaryDec 2028
NCT02939573Colchicine (SAP-001)Phase 2Primary Cutaneous VasculitisImmunologyDec 2028
NCT06578182Colchicine (SAP-001)Phase 3Osteoarthritis, KneeImmunologyMar 2029
NCT07536373Colchicine (SAP-001)Phase 3Chronic Limb-Threatening IschemiaCardiovascularApr 2029
NCT04774159Colchicine (SAP-001)Phase 3Peripheral Arterial DiseaseCardiovascularDec 2029
NCT07349875Colchicine (SAP-001)Phase 4Coronary Artery Disease (CAD)CardiovascularDec 2029
NCT05949281Colchicine (SAP-001)Phase 2Type 1 DiabetesCardiovascularJan 2031
NCT06930885Colchicine (SAP-001)Phase 3Atherothrombotic DiseasesCardiovascularMay 2031
NCT07232069Colchicine (SAP-001)Phase 3Coronary Artery Disease Risk Factors MultipleCardiovascularJul 2031

Targets

Tubulin (1)

Companies with the same targets

Roche Takeda Sichuan Kelun-Biotech Biopharmaceutical Pfizer AbbVie RemeGen Fidia Farmaceutici GSK Beijing Biostar Pharmaceuticals Urotronic

Companies built like this

Gradalis Beijing Biostar Pharmaceuticals Merz Therapeutics ArthroBiologix CellTrans

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.